HomeCompareMIFF vs ABBV

MIFF vs ABBV: Dividend Comparison 2026

MIFF yields 5.65% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $46.0K in total portfolio value
10 years
MIFF
MIFF
● Live price
5.65%
Share price
$26.00
Annual div
$1.47
5Y div CAGR
19.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.3K
Annual income
$8,447.07
Full MIFF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MIFF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMIFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MIFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MIFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MIFF
Annual income on $10K today (after 15% tax)
$480.58/yr
After 10yr DRIP, annual income (after tax)
$7,180.01/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $13,875.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MIFF + ABBV for your $10,000?

MIFF: 50%ABBV: 50%
100% ABBV50/50100% MIFF
Portfolio after 10yr
$79.3K
Annual income
$16,609.42/yr
Blended yield
20.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MIFF
No analyst data
Altman Z
0.3
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MIFF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMIFFABBV
Forward yield5.65%3.06%
Annual dividend / share$1.47$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR19.9%40.6%
Portfolio after 10y$56.3K$102.3K
Annual income after 10y$8,447.07$24,771.77
Total dividends collected$30.7K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MIFF vs ABBV ($10,000, DRIP)

YearMIFF PortfolioMIFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,378$677.90$11,550$430.00$172.00ABBV
2$13,039$864.29$13,472$627.96$433.00ABBV
3$15,061$1,109.86$15,906$926.08$845.00ABBV
4$17,552$1,436.58$19,071$1,382.55$1.5KABBV
5$20,657$1,876.00$23,302$2,095.81$2.6KABBV
6$24,577$2,474.01$29,150$3,237.93$4.6KABBV
7$29,595$3,298.37$37,536$5,121.41$7.9KABBV
8$36,118$4,450.77$50,079$8,338.38$14.0KABBV
9$44,733$6,086.51$69,753$14,065.80$25.0KABBV
10$56,311$8,447.07$102,337$24,771.77$46.0KABBV

MIFF vs ABBV: Complete Analysis 2026

MIFFStock

Mifflinburg Bancorp, Inc. operates as a bank holding company for Mifflinburg Bank and Trust Company that provides various commercial banking products and services. It offers checking and savings accounts; certificates of deposits; and home, personal, auto, medical/professional, farm/agricultural, and non-profit loans; lines of credit and overdrafts; credit cards; merchant card, lock box processing, remote deposit, CD file storage, safe and night deposit box, automatic transfers, notary, stop payment orders, and wire transfer services; and investment products comprising retirement, college funding, life insurance, brokerage, and investment analysis services, as well as online and mobile banking services. The company operates 8 offices and 15 ATMs. Mifflinburg Bancorp, Inc. was founded in 1872 and is based in Mifflinburg, Pennsylvania.

Full MIFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MIFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MIFF vs SCHDMIFF vs JEPIMIFF vs OMIFF vs KOMIFF vs MAINMIFF vs JNJMIFF vs MRKMIFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.